Russian peptide research.
Follow the design.
From protein fragments to synthetic mimetics: a map of related molecules, original experiments and unresolved source trails.
Closely related analogues share one card where that makes comparison clearer. Each family page separates its members, source types and findings. Code names in a patent are not a catalogue of proven therapies.
Three ways into short-peptide research
Reproduce part of a protein
NGF, BDNF, NT-3 and NT-4 mimetics test whether selected structural loops can reproduce particular signaling responses. Even small structural changes can alter the measured biological effect.
GK-2 versus GK-6 primary study ↗Trace an active fragment
Myelopeptides and glyprolins connect tissue fractions with defined sequences. Detecting a peptide, proposing its protein origin and demonstrating a physiological function are separate questions.
MP-4 isolation and cell research ↗Start from a drug’s structure
The Zakusov developers describe piracetam-inspired Noopept and sulpiride-inspired Dilept as a distinct approach. Their historical account belongs alongside the original experiments, not in place of them.
Developer design account ↗Explore the families
NGF mimetics: GK & GTS series ↗
A family of experimental peptides designed from exposed loops of nerve growth factor. Related structures can differ in cell survival, differentiation and pain responses.
No human treatment trial assessed for this family
FAMILY RECORDBDNF mimetics: GSB, GBK & GTS ↗
Small experimental mimetics of different BDNF loops, grouped for comparison of chemistry, signaling and behavioral results.
No human treatment trial assessed for this family
FAMILY RECORDNT-3 mimetics: GTS-301 & GTS-302 ↗
A paired NT-3 research record comparing two loop-4 mimetics with different downstream signaling and animal pharmacology.
No human treatment trial assessed for this family
PEPTIDE RECORDGZS-411 ↗
A 2026 experimental dimeric dipeptide designed from NT-4 loop 1. Its currently linked findings are cell-based.
No human treatment trial assessed for this family
FAMILY RECORDCPG & GZK-111 ↗
A grouped record for endogenous cyclo(Pro-Gly), its experimental linear precursor GZK-111 and the connection to Noopept metabolism.
No human treatment trial assessed for this family
FAMILY RECORDGlyprolins & PGP hybrids ↗
A family record separating simple Pro/Gly peptides, PGP-containing hybrids and proposed protein-fragment lineages.
No human treatment trial assessed for this family
FAMILY RECORDMyelopid & MP-1–MP-6 ↗
A marrow-peptide family separating the original mixture from defined isolates and later synthetic research. Each member needs its own evidence.
No human treatment trial assessed for this family
FAMILY RECORDSedatin & dermorphin analogues ↗
A family of synthetic dermorphin-related peptides studied in tissue homeostasis, oxidative injury and opioid pharmacology.
No human treatment trial assessed for this family
FAMILY RECORDNALE & peptide G ↗
An experimental non-opiate leu-enkephalin analogue used to investigate cytoprotection apart from conventional opioid effects.
No human treatment trial assessed for this family
FAMILY RECORDGB-115 & CCK analogues ↗
A synthetic CCK-4-related dipeptide mimetic with animal studies and early human anxiety reports; its analogue library belongs on a shared research card.
31-patient pilot and possibly overlapping 25-patient conference analysis
FAMILY RECORDLiberol / TRH research ↗
An archival occupational-research record for the Liberol/TRH branch, covering historical human functional-reserve experiments.
Human dissertation material; original scan and study design pending
FAMILY RECORDBestim ↗
A gamma-linked D-Glu/L-Trp dipeptide studied in immune-cell binding experiments. It is distinct from Thymogen and Thymodepressin.
No human treatment trial assessed for this family
FAMILY RECORDImunofan ↗
A synthetic RDKVYR hexapeptide with laboratory immune and tissue-repair research. Historical Thymohexin nomenclature contains conflicting sequence order.
No human treatment trial assessed for this family
FAMILY RECORDGepon & ezrin-derived peptides ↗
An ezrin-related peptide family, distinct from thymic extracts and marrow-derived myelopeptides. The current record establishes a patent identity trail.
No human treatment trial assessed for this family
What changes in the existing map?
- Noopept: original CPG-metabolism evidence and the separate GZK-111 precursor program.
- Dilept: the psychiatric pilot, metabolite GZR-125 and animal withdrawal studies, kept separate from environmental testing.
- Semax and Selank: glyprolin design history, including a direct experiment showing that short PGP peptides did not reproduce Semax’s expression pattern.
- Dalargin: separate NALE and Sedatin branches, including the 2026 NOP-blockade follow-up.
- Thymogen and Thymohexin: Bestim binding and the Imunofan sequence distinction.
Sources still needed
These leads remain visible without being presented as established mechanisms, new clinical indications or independent replications.
FMRFamide, FaRPs & peptide mixtures
The 1996 rat resuscitation citation and Krushinskaya’s hemorrhage/hypobaric-hypoxia dissertation provide an archival route. Recover the exact sequences, mixture composition and original experimental tables before extracting claims.
Indexed animal-study citation ↗
Dissertation source ↗Hydra morphogen & CRH fragments
PMH/Hydra head-activator analogues and Pro–Pro–Ile (CRH 2–4) remain acquisition targets. Historical sequence transcriptions and mammalian immunoreactivity require original analytical confirmation.
Cryptides and neighboring programs
MP-2/hemorphin relationships, spinorphin/tynorphin, GPE and hydroxyproline peptides need sequence-specific primary records. A common fragment motif alone does not establish origin, receptor action or clinical benefit.
Unresolved analogue libraries
A10/A17/A43 now have a transcribed sequence table, but the original scan remains needed. GB-101, GBK-108/201 and GK-2f need complete member-specific assay mapping. The 2026 NT-3 stroke citation, Myelopeptides monograph and proposed extended NT-4 library also require further recovery.
Other immune-peptide lineages
Likopid/GMDP and the historical Blastolysin trail are separate bacterial cell-wall research, not evidence for thymic or marrow peptides. Deltaran formulation research should remain under the existing DSIP record.
DSIP and formulation distinctions ↗